欢迎您！东篱公司
退出
-
申报数据库
-
立项数据库
-
成果数据库
-
项目获奖数据库
中文摘要：
心力衰竭（HF）是多种心血管疾病的最终临床转归，其中心脏病理性重构是HF重要的病理生理基础。目前尚缺乏针对心脏病理性重构的特异性治疗手段，因此目前对于HF的治疗尚无法从本质上改变其生物学特性。组蛋白去乙酰化酶（HDACs）作为一种重要的表观遗传调控机制，已经被证实参与调控多条心脏病理性进程通路。同时多种针对特定HDACs的靶向干预药物已经面试，这为HF的治疗提供了全新的视角和思路。本文将对HDACs在心脏病理性重构中的意义及潜在靶向干预靶点进行综述。
英文摘要：
Heart failure is the terminated stage of most kinds of cardiovascular diseases and the cardiac pathological remodeling is the most essential part during such pathophysiological procedure. At present, there is still no specific therapy for heart failure, targeting its biological changes. Histone deacetylases （HDACs） have been proved to be involved in several regulation pathways in pathological process, one important epigenetic mechanism. Moreover, several kinds of targeted medications for specific HDACs have been developed, which provides new insights in treatment of heart failure. In this article, we will summary the functions and regulatory roles of HDACs in cardiac pathological procedure and their potential therapeutic targets.
同期刊论文项目
同项目期刊论文
期刊信息
位置：